Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
Neuroendocrine tumors
Positron emission tomography computed tomography
Somatostatin
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
02
09
2022
accepted:
06
02
2023
revised:
16
01
2023
medline:
25
4
2023
pubmed:
26
3
2023
entrez:
25
3
2023
Statut:
ppublish
Résumé
The recently proposed standardized reporting and data system for somatostatin receptor (SSTR)-targeted PET/CT SSTR-RADS 1.0 showed promising first results in the assessment of diagnosis and treatment planning with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). This study aimed to determine the intra- and interreader agreement of SSTR-RADS 1.0. SSTR-PET/CT scans of 100 patients were independently evaluated by 4 readers with different levels of expertise according to the SSTR-RADS 1.0 criteria at 2 time points within 6 weeks. For each scan, a maximum of five target lesions were freely chosen by each reader (not more than three lesions per organ) and stratified according to the SSTR-RADS 1.0 criteria. Overall scan score and binary decision on PRRT were assessed. Intra- and interreader agreement was determined using the intraclass correlation coefficient (ICC). Interreader agreement using SSTR-RADS 1.0 for identical target lesions (ICC ≥ 0.91) and overall scan score (ICC ≥ 0.93) was excellent. The decision to state "functional imaging fulfills requirements for PRRT and qualifies patient as potential candidate for PRRT" also demonstrated excellent agreement among all readers (ICC ≥ 0.86). Intrareader agreement was excellent even among different experience levels when comparing target lesion-based scores (ICC ≥ 0.98), overall scan score (ICC ≥ 0.93), and decision for PRRT (ICC ≥ 0.88). SSTR-RADS 1.0 represents a highly reproducible and accurate system for stratifying SSTR-targeted PET/CT scans with high intra- and interreader agreement. The system is a promising approach to standardize the diagnosis and treatment planning in NET patients. • SSTR-RADS 1.0 offers high reproducibility and accuracy. • SSTR-RADS 1.0 is a promising method to standardize diagnosis and treatment planning for patients with NET.
Identifiants
pubmed: 36964768
doi: 10.1007/s00330-023-09518-y
pii: 10.1007/s00330-023-09518-y
pmc: PMC10121493
doi:
Substances chimiques
Receptors, Somatostatin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3416-3424Informations de copyright
© 2023. The Author(s).
Références
Hofman MS, Lau WF, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500–516
doi: 10.1148/rg.352140164
pubmed: 25763733
Shastry M, Kayani I, Wild D et al (2010) Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 31:1025–1032
doi: 10.1097/MNM.0b013e32833f635e
pubmed: 20926978
Werner RA, Solnes LB, Javadi MS et al (2018) SSTR-RADS Version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: a proposed standardization framework. J Nucl Med 59:1085–1091
doi: 10.2967/jnumed.117.206631
pubmed: 29572257
Bozkurt MF, Virgolini I, Balogova S et al (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging 44:1588–1601
doi: 10.1007/s00259-017-3728-y
pubmed: 28547177
Geijer H, Breimer LH (2013) Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 40:1770–1780
doi: 10.1007/s00259-013-2482-z
pubmed: 23873003
Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ (2007) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46:723–734
doi: 10.1080/02841860701441848
pubmed: 17653893
Zidan L, Iravani A, Kong G, Akhurst T, Michael M, Hicks RJ (2021) Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on (68)Ga-DOTATATE PET/CT and (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 48:204–216
doi: 10.1007/s00259-020-04915-7
pubmed: 32572559
Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135
doi: 10.1056/NEJMoa1607427
pubmed: 28076709
pmcid: 5895095
Strosberg J, Wolin E, Chasen B et al (2018) Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with (177)Lu-dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 36:2578–2584
doi: 10.1200/JCO.2018.78.5865
pubmed: 29878866
pmcid: 6366953
Kwekkeboom DJ, Kam BL, van Essen M et al (2010) Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17:R53-73
doi: 10.1677/ERC-09-0078
pubmed: 19995807
Krenning EP, Kwekkeboom DJ, Bakker WH et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731
doi: 10.1007/BF00181765
pubmed: 8404961
Hicks RJ, Dromain C, de Herder WW et al (2022) ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. J Neuroendocrinol 34:e13040
doi: 10.1111/jne.13040
pubmed: 34668262
Weich A, Higuchi T, Bundschuh RA et al (2022) Training on Reporting and Data System (RADS) for somatostatin-receptor targeted molecular imaging can reduce the test anxiety of inexperienced readers. Mol Imaging Biol. https://doi.org/10.1007/s11307-022-01712-6
doi: 10.1007/s11307-022-01712-6
pubmed: 35312939
pmcid: 9296404
Werner RA, Derlin T, Rowe SP et al (2021) High interobserver agreement for the standardized reporting system SSTR-RADS 1.0 on somatostatin receptor PET/CT. J Nucl Med 62:514–520
doi: 10.2967/jnumed.120.245464
pubmed: 32859702
pmcid: 8049367
Cicchetti D (1994) Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instrument in psychology. Psychol Assess 6:284–290
doi: 10.1037/1040-3590.6.4.284
Diedenhofen B, Musch J (2016) cocron: a web interface and R package for the statistical comparison of Cronbachʼs alpha coefficients. Int J Internet Sci 2016:51–60
Fendler WP, Barrio M, Spick C et al (2017) 68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: results of a prospective study on 50 patients. J Nucl Med 58:307–311
doi: 10.2967/jnumed.116.179192
pubmed: 27539839
pmcid: 5290122
Werner RA, Weich A, Kircher M et al (2018) The theranostic promise for neuroendocrine tumors in the late 2010s - where do we stand, where do we go? Theranostics 8:6088–6100
doi: 10.7150/thno.30357
pubmed: 30613284
pmcid: 6299695
Ambrosini V, Kunikowska J, Baudin E et al (2021) Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 146:56–73
doi: 10.1016/j.ejca.2021.01.008
pubmed: 33588146
pmcid: 8903070
Herrmann K, Giovanella L, Santos A et al (2022) Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. J Nucl Med. https://doi.org/10.2967/jnumed.122.264321
doi: 10.2967/jnumed.122.264321
pubmed: 36581374
pmcid: 9536712
Fendler WP, Calais J, Allen-Auerbach M et al (2017) (68)Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med 58:1617–1623
doi: 10.2967/jnumed.117.190827
pubmed: 28408531
Woodhouse B, Pattison S, Segelov E et al (2019) Consensus-derived quality performance indicators for neuroendocrine tumour care. J Clin Med 8(9). https://doi.org/10.3390/jcm8091455
Kumar R, Sharma P, Garg P et al (2011) Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 21:2408–2416
doi: 10.1007/s00330-011-2199-y
pubmed: 21750886
Werner RA, Bundschuh RA, Bundschuh L et al (2018) Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Ann Nucl Med 32:512–522
doi: 10.1007/s12149-018-1291-7
pubmed: 30109562
pmcid: 6182628
Werner RA, Bundschuh RA, Bundschuh L et al (2019) Novel structured reporting systems for theranostic radiotracers. J Nucl Med 60:577–584
doi: 10.2967/jnumed.118.223537
pubmed: 30796171
pmcid: 6495242